OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE) (Paris:OSE) and the FoRT Foundation (Fondazione Ricerca Traslazionale) announced today that the first patient has been randomized in the ...

PARIS & NANTES, France--(BUSINESS WIRE)--Regulatory News: Servier, an independent global pharmaceutical group, and OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnémo: OSE) (Paris:OSE), a French ...

OSE Immunotherapeutics has kicked off a strategic realignment initiative that involves deprioritizing the AbbVie-partnered OSE-230 and focusing its resources on the late-stage development of its ...

OSE Immunotherapeutics is hoping to show Servier what they walked away from. Around one year after the French drugmakers split up, the biotech has reported midphase data on an anti-IL-7 antibody ...

OSE Immunotherapeutics Announces Positive Efficacy Results for Lusvertikimab in the Phase 2 trial for the treatment of Ulcerative Colitis Lusvertikimab demonstrates significant efficacy during the 10 ...

Ose Immunotherapeutics is prioritizing its lung cancer med Tedopi and shifting the strategy for its ulcerative colitis (UC) therapy lusvertikimab as the French biotech maps out a financially ...

OSE Immunotherapeutics Reports Full Phase 2 Induction Results for Anti-IL-7R mAb Lusvertikimab in Ulcerative Colitis at the 20 th Congress of ECCO NANTES, France – February 24, 2025, 7:30am CET - OSE ...

Republican former Rep. Doug Ose was the seventh major candidate to enter the 2018 governor’s race. He brings the most political experience of the Republicans in the contest. Here are five things you ...

German sex-toy maker Novoluto has obtained a default judgment of more than $2 million against Uccellini, the Oregon sex-tech startup also known as Lora DiCarlo, in a patent-infringement lawsuit filed ...

MI-Common Data Model: Extending Observational Medical Outcomes Partnership-Common Data Model (OMOP-CDM) for Registering Medical Imaging Metadata and Subsequent Curation Processes The Osteosarcoma ...

Nantes, France, March 10, 2026 - 7:30am CET - OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE), today announced the ...

No impact on cash runway or financing strategy as no milestone associated with these programs was expected within this three-year timeframe Focused investment on high‑value late‑stage assets ...